The bioscience industry and its supporting ecosystem drive bold innovations to address unmet human needs in the U.S. and around the world, including developing new breakthrough therapies that treat deadly diseases. The collective efforts of the industry and our public and private stakeholders have met the challenges of the COVID pandemic head-on, while lessening the impacts of climate change and nourishing a growing global population. 

There is a misguided perception that NIH funding, not private market investment, is largely responsible for the creation and approval of new therapies. A new study by Vital Transformation¹ tests that hypothesis by tracking more than 20,000 patents linked to NIH grant over a 20 year period, identifying those associated with clinical trials and approved medicines, and quantifying the public and private investments made for those investigational and approved medicines.